Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: A case series.
Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: A case series.
复制标题
DOI：
10.1111/jcpt.13317
复制
发表时间：
2021-04
影响因子：
2
通讯作者：
Kram B
中科院分区：
文献类型：
--
作者：
Spivey J;Wrenn R;Liu B;Maziarz E;Kram B
侵袭性真菌感染经常发生在患有使口服给药复杂化的合并症的患者中。肠内管给药后测定艾沙康唑的血清浓度。在接受肠管给药的患者中，14 种艾沙康唑中有 13 种的浓度 >1 mg/dl（中位值 1.6 mg/dl），与静脉注射（中位值 1.9 mg/dl）相当。口服给药期间观察到较高的浓度（中位值 3 mg/dl）。通过管给予艾沙康唑的浓度与 FDA 批准的给药途径相当。该途径可能是可行的并且适合特定的患者。
Invasive fungal infections often occur in patients with comorbidities that complicate oral administration. Serum concentrations of isavuconazole were characterized after enteral tube administration. Thirteen of 14 isavuconazole concentrations were >1 mg/dl (median 1.6 mg/dl) among those receiving enteral tube administration, which was comparable to intravenous (median 1.9 mg/dl). Higher concentrations were observed during oral administration (median 3 mg/dl). Administration of isavuconazole via tube resulted in concentrations comparable to FDA-approved routes of administration. This route may be feasible and appropriate for select patients.
登录
查看更多内容
影响因子：
2.6
作者：
Adamsick, Meagan L.;Elshaboury, Ramy H.;Gandhi, Ronak G.
通讯作者：
Gandhi, Ronak G.
影响因子：
11.8
作者：
Park, Wan Beom;Kim, Nak-Hyun;Yu, Kyung-Sang
通讯作者：
Yu, Kyung-Sang
影响因子：
4.9
作者：
Desai AV;Kovanda LL;Hope WW;Andes D;Mouton JW;Kowalski DL;Townsend RW;Mujais S;Bonate PL
通讯作者：
Bonate PL
影响因子：
11.8
作者：
Fontana, Lauren;Perlin, David S.;Hakki, Morgan
通讯作者：
Hakki, Morgan
影响因子：
11.8
作者：
Park BJ;Pappas PG;Wannemuehler KA;Alexander BD;Anaissie EJ;Andes DR;Baddley JW;Brown JM;Brumble LM;Freifeld AG;Hadley S;Herwaldt L;Ito JI;Kauffman CA;Lyon GM;Marr KA;Morrison VA;Papanicolaou G;Patterson TF;Perl TM;Schuster MG;Walker R;Wingard JR;Walsh TJ;Kontoyiannis DP
通讯作者：
Kontoyiannis DP